Stereotaxis (NYSE:STXS) announced today that it received FDA 510(k) clearance for its next-generation GenesisX surgical robot.
ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback